Abstract 198P
Background
Lenvatinib is oral tyrosine kinase inhibitor (TKI) that has been available for treatment of unresectable hepatocellular carcinoma (uHCC) in Japan since March 2018. We conducted a multicenter prospective observational study to assess overall survival (OS) of lenvatinib treatment in real world practice.
Methods
This study enrolled patients initially receiving lenvatinib for uHCC as systemic therapy who gave informed consent from July 2018 through January 2019. Observation period for each patient was up to 3 years. Kaplan-Meier method was used to estimate OS, and Cox regression analysis was used to explore factors which were associated with OS. The factors were selected with p value <0.05.
Results
A total of 713 patients were registered at 137 clinical sites, and the effectiveness analysis set were 703 patients. Patient background characteristics in 703 patients included median age:73.0 years (25 to 94), male/female: 564/139, weight: <60/≥60 kg :323/380 ,HBV/HCV/alcohol/NAFLD or NASH :137/287/167/88, modified ALBI grade 1/2a/2b/3 :216/199/258/18, BCLC stage A/B/C/D :57/291/332/11, Vp 0/1/2/3/4 :520/31/52/60/22, with/without extrahepatic metastasis :229/450, AFP level <200/≥200 ng/mL :432/240. Treatment history for uHCC was with/without transcatheter arterial chemoembolization (TACE): 513/190, median number of TACE: 3.0 times (1 to 26), with/without TKI pretreatment: 131/572. The initial dose of lenvatinib were labeled dose in 80.5% of patients <60 kg (8 mg) and 68.2% of patients ≥60 kg (12 mg), respectively. The median (range) duration of treatment with lenvatinib was 186.0 days (2-1,099 days). The median OS (95% CI) was 1.38 years (1.29-1.54 years) and the number of deaths was 445 patients. As a result of multivariate analysis, low ECOG-PS, low modified ALBI grade, low AFP level, small number of intrahepatic lesions, no bile duct involvement, no portal vein involvement and no extrahepatic involvement at baseline were associated with longer median OS.
Conclusions
This analysis showed that the effectiveness of lenvatinib in real world practice were consistent with previous reports.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Co., Ltd.
Funding
Eisai Co., Ltd.
Disclosure
N. Izumi: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, Chugai, Takeda, Lily. K. Motoyoshi: Financial Interests, Personal, Full or part-time Employment: eisai. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sannofy, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incy; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofy, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. All other authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract